Skip to main content

Table 4 Use of vascular disease preventative drugs by geographical region

From: Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study

Ā 

All

China

South Asia

East Asia

North Africa

Middle East

Latin America

Russia

Patients with macrovascular complications

Ā Ā Ā Ā Ā Ā Ā Ā 

RAS blocker, n (%)

13,910 (78.1)

1,303 (55.6)

3,771 (76.3)

1,992 (74.2)

778 (79.5)

3,719 (86.6)

285 (85.1)

2,062 (92.6)

Aspirin, n (%)

13,995 (78.6)

1,644 (70.2)

3,784 (76.6)

1,866 (69.5)

801 (81.8)

3,973 (92.5)

252 (75.2)

1,675 (75.2)

Statins, n (%)

11,958 (67.2)

1,139 (48.6)

3,057 (61.9)

1,846 (68.8)

715 (73.0)

3,710 (86.4)

189 (56.4)

1,302 (58.5)

Patients with microvascular complications

Ā Ā Ā Ā Ā Ā Ā Ā 

RAS blocker, n (%)

21,884 (62.6)

2,268 (41.5)

4,792 (58.5)

3,465 (61.7)

1,557 (65.0)

6,907 (70.1)

499 (69.8)

2,396 (87.3)

Aspirin, n (%)

22,207 (63.5)

2,704 (49.5)

4,958 (60.6)

2,698 (48.0)

1,598 (66.7)

7,922 (80.5)

427 (59.7)

1,900 (69.2)

Statins, n (%)

19,709 (56.4)

1,856 (33.9)

4,325 (52.8)

3,133 (55.8)

1,288 (53.7)

7,323 (74.4)

312 (43.6)

1,472 (53.6)

  1. Note: due to the observational nature of this study, not all baseline data were recorded.
  2. RASā€‰=ā€‰renin-angiotensin system.